Scpharmaceuticals Inc (OQ:SCPH)

Sector:  Healthcare Industry:  Pharmaceuticals
 
See Regulatory Filings on SEC
Company Contact
Address: 25 Burlington Mall Road, Suite 203
BURLINGTON MA 01803
Tel: 1-781-3016706
Website: https://www.scpharmaceuticals.com
IR: See website
<
Key People
John H. Tucker
President, Chief Executive Officer, Director
Rachael Nokes
Chief Financial Officer
 
Business Overview
scPharmaceuticals Inc. is a pharmaceutical company. The Company is focused on developing and commercializing products to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The Company develops, internally and through strategic partnerships, products and solutions that aim to expand and advance the outpatient care of select acute conditions. Its lead product candidate, FUROSCIX, consists of its formulation of furosemide delivered via an on-body infuser. FUROSCIX is a formulation of furosemide contained in a pre-filled, Crystal Zenith cartridge and self- administered subcutaneously via a single-use, disposable and wearable on-body delivery system. The Companay's pipeline programs include SCP-111 (furosemide injection) 80mg/mL is an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home.
Financial Overview
For the fiscal year ended 31 December 2023, Scpharmaceuticals Inc revenues increased from $0K to $13.6M. Net loss increased 49% to $54.8M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects PHARMACEUTICAL PREPARATIONS segment loss increase of 53% to $55.4M.
Employees: 135 as of Mar 12, 2024
Reporting Currency: U.S. Dollars
Enterprise value: $125.40M as of Dec 31, 2023
Annual revenue (TTM): $13.59M as of Dec 31, 2023
EBITDA (TTM): -$55.37M as of Dec 31, 2023
Net annual income (TTM): -$54.81M as of Dec 31, 2023
Free cash flow (TTM): -$59.28M as of Dec 31, 2023
Net Debt Last Fiscal Year: N/A
Shares outstanding: 36,054,409 as of Mar 12, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.